BrightEdge propels groundbreaking patient-centric solutions by accelerating ACS’s mission to advance science, reducing disparities, and promoting healthcare sustainability.
About
BrightEdge propels groundbreaking patient-centric solutions by accelerating ACS’s mission to advance science, reducing disparities, and promoting healthcare sustainability.
Our Mission
Leading the fight for a world without cancer.
BrightEdge operates at the intersection of impact, innovation, and investment to accelerate the American Cancer Society’s goal to reduce cancer mortality.
Our Connection
BrightEdge leverages ACS’s unparalleled knowledge base to catalyze impact innovation by strategically investing in entrepreneurial early-stage companies
$5.0b+
Invested in Research Since 1946
49
Nobel Laureates
31%
Decline in Mortality Rate Since 1991
Investing for Real Impact
BrightEdge invests for and drives ACS mission through high-quality deals and patient-centric innovation and generates market-rate returns
• Financial returns realized from investments are reinvested and/or returned to ACS, building a diversified and sustainable source of funding for the ACS’s life-saving body of work.
• Donations to BrightEdge will become a sustainable source of financial support for the American Cancer Society to provide needed services locally to people facing cancer today and tomorrow in more than 5,000 communities.
• Investment returns from the BrightEdge portfolio are both reinvested in the BrightEdge fund and used to sustain American Cancer Society’s life-saving programs in research, access, and health equity.
BrightEdge Portfolio Companies are...
Attacking Cancer
Propelling groundbreaking patient-centric solutions to accelerate the ACS’s mission to advance science, reduce disparities, and promote healthcare sustainability.
Focused on Health Equity
Seeking to broaden and accelerate patient access to life-saving innovations by developing technology-enabled solutions that will transform the way healthcare is delivered and experienced.
In All Stages of Development
Stage-agnostic as BrightEdge invests in seed-stage companies, businesses raising crossover rounds, and everything in between.
Funded by Industry-Leading VCs
BrightEdge invests alongside the industry’s top VC funds to accelerate the most innovative companies that are raising capital through equity or convertible debt. (Note that while ACS Research distributes over one hundred million dollars of translational grants per year, the BrightEdge fund does not provide grant funding.) BrightEdge plays a unique role by bringing system-level knowledge to early-stage companies at critical points in product strategy and helps portfolio companies access world-class intellectual and human capital as they grow.